

Traveler Evaluation and Monitoring Protocol

Interim Guidance for the Michigan Department of Health and Human Services (MDHHS) and Local Health Departments (LHD)

Traveler Evaluation and Monitoring (TEAM) Protocol for Marburg Virus Disease (MVD) 2023

I. Background MDHHS

- This document reviews the management of travelers from areas currently experiencing an outbreak of Marburg virus disease (MVD). MVD is a rare, but severe hemorrhagic fever which affects both people and non-human primates. Like Ebola, Marburg is a member of the family *Filoviridae*. Currently, outbreaks have been identified in Equatorial Guinea and Tanzania. Please see the Centers for Disease Control and Prevention (CDC) websites for the most current information:
Marburg Virus Disease: <https://www.cdc.gov/vhf/marburg/index.html>
Marburg Virus Disease Outbreaks: <https://www.cdc.gov/vhf/marburg/outbreaks/chronology.html>
- MDHHS will be notified of travelers from Equatorial Guinea or Tanzania who have travel plans continuing to Michigan. Travelers may be provided with instructions to self-monitor for illness.
- Once MDHHS is notified that a traveler from an MVD-impacted area plans to arrive in Michigan, MDHHS will enter the contact information into the Outbreak Management System (OMS) and notify the LHD.
- **Currently, CDC does not recommend health departments conduct risk assessments or monitoring for travelers returning from MVD-impacted areas.**
- **Traveler data will be available on the OMS portal should any Michigan Local Health Departments choose to conduct follow-up activities such as risk assessment or monitoring.**

II. Background LHD

- Available contact information for travelers will be shared with LHDs through OMS via the following outbreak names:
 - MARBURG-2023-EQUATORIAL-GUINEA
 - MARBURG-2023-TANZANIA
- No formal recommendations have been issued on following-up with travelers from MVD-impacted countries. LHDs may choose to contact travelers to conduct an initial risk and health assessment and to provide health education. Travelers have not been issued any restrictions on travel or movement.
- If a risk assessment is performed, questions could include whether the traveler:
 - was present in an MVD-impacted country in the past 21 days (if not, stop assessment; document response clearly in OMS, select Risk Assessment level as “Zero”, and update status to “Canceled” in OMS)
 - was present (other than just transiting en route to airport) in a MVD outbreak area
 - had any epidemiologic risk factors for exposure to Marburg virus or a person with MVD, e.g., as a caregiver, healthcare provider, laboratory worker, or burial worker
 - had any potential high-risk exposures
 - used personal protective equipment and other recommended infection control measures during any potential exposure and if there were any potential breaches
 - has any [signs and symptoms](#) of MVD

- Health education for the traveler could include:
 - how to monitor themselves for signs and symptoms of MVD
 - to self-isolate immediately if any symptoms develop
 - **how to notify public health officials should symptoms develop**
 - Until additional CDC information is provided, the following exposures are considered High-Risk:
 - Percutaneous (i.e., piercing the skin), mucous membrane (e.g., eye, nose, or mouth), or skin contact with blood or body fluids¹ of a person with known or suspected MVD
 - Direct contact with person who has known or suspected MVD
 - Providing health care to a patient with known or suspected MVD without use of recommended personal protective equipment (PPE)², or experiencing a breach in infection control precautions that results in the potential for percutaneous, mucous membrane, or skin contact with the blood or body fluids of a patient with MVD
 - Direct contact with or the occurrence of a breach in infection control precautions while handling a dead body in a MVD outbreak area, the body of a person who died of MVD or had an illness compatible with MVD, or who died of unknown cause after any potential exposure to Marburg virus
 - Living in the same household as a person with symptomatic known or suspected MVD
- ¹ Examples of body fluids: feces, saliva, sweat, urine, vomit, sputum, breast milk, tears, and semen.
- ² Recommended PPE should prevent skin or mucous membrane exposure to blood or body fluids.
- At this time, the following criteria can be used to determine the “Risk Assessment” field in OMS:
 - High-Risk=high
 - Present in Outbreak Area=some
 - Present in Outbreak Country but not Outbreak Area=low
 - If a LHD chooses to conduct symptom monitoring for the balance of the 21-day observation period using the OMS, the following guidelines may be followed:
 - Establish rapport, assess compliance, and set the schedule for follow-up.
 - Contact the traveler via e-mail, text, or phone to check on health status.
 - Record updates in the OMS.
 - **If a traveler from an MVD-impacted country develops signs or symptoms compatible with MVD,** immediately report to MDHHS Communicable Disease Division at 517-335-8165. Please only use the OMS contact ID in emails to your Regional Epidemiologist and the Travelers Health team at MDHHS-TravelersHealth@michigan.gov.

III. TEAM Protocol MDHHS:

- Monitor for reports of individuals traveling to Michigan that need monitoring.
- Enter newly identified traveler information into the OMS and inform the MDHHS SHARP Unit.
- Regional Epidemiologists notify LHD of new travelers identified via Epi-X or other mechanisms.
 - LHD roles to be notified: Health Officer, Medical Director, Emergency Preparedness Coordinator, CD Coordinator, and Epidemiologist(s)
- As requested, provide updates to CDC.

IV. TEAM Protocol: LHD

NOTE: This section only applicable for LHDs choosing to monitor travelers

- Receive traveler information via OMS.
 - a. "Referral Date" field should remain as entered by MDHHS, regardless of date of first contact.
- If unable to reach the traveler with the contact information provided, leave "Monitoring Status" as "New". **See Appendix for complete [Data Entry Instructions for OMS](#).
- If the traveler is not currently in Michigan, notify MDHHS and stop follow-up with the traveler. In OMS, change "Monitoring Status" accordingly:
 - a. Traveler never arrived nor intends to arrive in Michigan = "Canceled"
 - b. Traveler arrived in Michigan, but is traveling to another state or country after active monitoring has been initiated = "Left Jurisdiction"
- Based on the initial assessment, define the 21-day monitoring period and record start and end dates under the Data Points tab.
 - a. If unable to contact the traveler successfully, leave "Start Monitoring Date" and "End Monitoring Date" fields empty.
 - b. Record the date traveler was last exposed as "Start Monitoring Date". This reflects the last date the traveler was in Equatorial Guinea or Tanzania.
 - c. When filling out the Days List, the last date of suspected exposure would be Day 1. For travelers, Day 1 is the date of departure from an MVD-impacted country.
 - i. Record date of departure under Risk Information on the Risk tab, inside detail section of "Has this person had any other possible exposures to this condition? If yes, provide details."
 - d. By default, Day 21 should be listed as the "End Monitoring Date". In the event the traveler is lost to follow up or monitoring is ending due to domestic or international travel outside the jurisdiction, the end monitoring date must be updated to the last date the traveler was or will be under LHD monitoring.
- Update missing OMS information (e.g., risk assessment, contact information, demographics, notes).
- Ensure traveler has a working thermometer and understands how to take their temperature. Determine type of thermometer (e.g., axillary, oral); obtain temperature and symptom check.
- Assess and report initial traveler compliance.
- Assess and confirm traveler understanding of the monitoring process.
- If the traveler reports fever (subjective fever or measured temperature $\geq 100.4^{\circ}\text{F}$) or symptoms (any of the following: vomiting, diarrhea, or unexplained bleeding or bruising):
 - o Inform them they will be contacted ASAP regarding possible medical evaluation.
 - o Remind the traveler to inform any healthcare provider of their MVD monitoring status **BEFORE** arrival at a healthcare facility or receiving any treatment (e.g., over the phone).
 - o Immediately contact appropriate LHD designee(s) and MDHHS at 517-335-8165 (or afterhours at 517-335-9030) for evaluation and/or coordination of care.
- During the last check-in of the 21-day monitoring period, inform traveler that no additional checks will be made. They should feel free to contact the LHD if they have any questions in the future.
 - o Update "Monitoring Status" field to "Complete". Ensure "Completion date" and "End monitoring date" reflect last successful contact date.

V. Guidance Language for LHDs Choosing to Monitor Travelers

- Based on your individual risk assessment, I will need health-checks from you once a day for the next XX days], obtaining information so that we can help you if you become ill while you are here. My direct phone number is: ___/___-____.
- I need you to continue to self-monitor for symptoms, including daily temperature checks. Do you have a thermometer? What type is it?
- If you do develop a fever or have any symptoms such as vomiting, diarrhea, or unexplained bruising or bleeding please call so that we can assist you in seeking care.
- If you are unable to reach me (or the local health department), please call the Michigan Department of Health and Human Services at 517-335-8165 (or afterhours at 517-335-9030).
- If you cannot reach anyone at the Michigan Department of Health and Human Services, please call 911 and tell them that you have recently come from _____ country on (___/___/___) date and that you have become ill.
- If you have a medical emergency during your 21-day monitoring period and call 911 before making other notifications, please tell them that you have recently come from _____ country on (___/___/___). We will remind you frequently of the need to notify hospital staff and/or EMS of your recent travel and MVD-monitoring status.

VI. Instructions for a Monitored Traveler who becomes Symptomatic:

- If a traveler reports subjective fever, a measured temperature ≥ 100.4 F, or other MVD-compatible symptoms (vomiting, diarrhea, unexplained bleeding or bruising, severe headache, muscle pain, or stomach pain) during the 21-day monitoring period:
 - Instruct traveler to isolate as much as possible within the home and await further instructions. Determine if traveler could drive to an identified hospital.
 - Contact MDHHS immediately at 517-335-8165 to assess traveler’s need for hospital care.
 - **If traveler requires hospital care and can drive:**
 - LHD contacts hospital to inform them and coordinate the traveler’s pending arrival.
 - Request that the hospital notifies the LHD and MDHHS when the traveler arrives.
 - Direct traveler to report immediately to the appropriate entry point at the pre-designated hospital via personal vehicle.
 - **If traveler requires hospital care and needs transport assistance:**
 - LHD contacts hospital to inform them and coordinate the traveler’s pending arrival.
 - Hospital or the LHD must inform EMS the traveler is currently under monitoring and coordinate transportation appropriately.
 - Direct traveler to wait for scheduled ambulance.
 - If traveler does not require hospital care, continue with monitoring.

VII. MDHHS Contact Information: [Epidemiology 517-335-8165](tel:517-335-8165) [Afterhours 517-335-9030](tel:517-335-9030)

Point of Contact

Telephone Number

Email Address


Appendix

Tip Sheet for OMS entry for Marburg Virus

The Travelers Health (TH) Team is responsible for tracking the outcome of monitoring across the State of Michigan. The purpose of this tip sheet is to standardize how local health departments (LHDs) are filling out fields within OMS, so that accurate reporting may occur. Please direct any questions to the TH Team at MDHHS-TravelersHealth@michigan.gov and CC: your [regional epidemiologist](#).


NOTE: The screenshots below are pulled from a previous Tip Sheet. Please refer to the screenshots only to help navigate OMS.

- Newly identified traveler information is entered into the Outbreak Management System (OMS) by the Travelers Health (TH) Team and Regional Epidemiologists



The screenshot shows the OMS interface with the 'Outbreak Monitoring Details' dropdown menu open. The menu lists several outbreak names, with 'EBOLA-2022-UGANDA' selected. The interface includes tabs for 'Administration', 'Outbreak Listing', and 'Contact List'. The 'Contact List' tab is active, and the 'New Contact' button is visible. The dropdown menu options are: COVID19_RIVERIDGE_AUGUST2022, DGI 2019, EBOLA DRC 2019, EBOLA-2019-MICHIGAN, EBOLA-2021-DRC-GUINEA, EBOLA-2022-UGANDA (selected), FARMINGTON HILLS EARLY ON PROGRAM 3.17.2022, FOODBORNE-2018-BERRIEN BIRTHDAY, and GI-JUNE2019-BEDHD.

- All known information is entered into corresponding appropriate fields. However, flight information will be included in the “Contact Parent/Guardian Information” section where First Name will be the DGMQ ID and Last Name will be flight details (flight carrier code, flight number, airport code, arrival city and arrival date as MM/DD/YYYY).



The screenshot shows the 'Contact Parent/Guardian Information' form. The fields are: First Name: RECORDID 40273406, Last Name: FLIGHT UA 973, ORD, CHICAGO, 11/13/2022, Middle Name: (empty), Relation: (empty), Primary Phone: (empty), Secondary Phone: (empty), and Email: (empty).

- Please leave these fields as entered. This information is listed here due to the restriction of fields that can be filled during a bulk OMS Upload.

- If contact is a minor, enter the Parent Details into the “Emergency Contact” section.

Note: The following OMS guidance is only intended for LHDs who choose to monitor travelers from MVD-impacted countries.

- On **Risk** page: Any additional information will be entered into the corresponding fields after the new record is created (such as Citizenship, Arrival Port, Arrival Date, etc.)
- LHD investigators may check the map for affected districts with each new traveler, as new districts are added or status for a particular district may have recently changed. Verify specific activities and districts traveled to in the affected country, categorizing the risk level according to MDHHS TEAM Protocol for Marburg. An up-to-date map of affected districts can be viewed under the Travel Health Notice webpages for [Equatorial Guinea](#) and [Tanzania](#).

Contact Travel Information		
Country of Exposure: --Country--	Port Of Entry: NEW YORK, JFK	Arrival to US: 10/27/2022
DGMQ ID: 39310630	Official ID:	Est. Departure from US:
Passport#	Issuing Country US	

Risk Information	
Is person a healthcare provider? If yes, provide details.	
<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown	
Has this person been around anyone else that is/was ill with this condition (dead/alive)? If yes provide details.	
<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown	
Has this person had contact with an animal associated with this condition? If yes, provide details.	
<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown	
Has this person had any other possible exposures to this condition? If yes, provide details.	
<input checked="" type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown	"EBOLAAREA" = YES
Has this person been exposed on a flight? If yes, provide details.	
<input type="radio"/> Yes <input type="radio"/> No <input type="radio"/> Unknown	

- Email your [Regional Epidemiologist](#), plus MDHHS-TravelersHealth@michigan.gov if the traveler:
 - cannot be reached by the LHD with the supplied contact information.
 - is not in Michigan upon initial contact by the LHD and/or will not be in Michigan at any point during monitoring period. The TH team will coordinate the transfer of this individual to the appropriate state for monitoring.

- Once your initial conversation is complete, ensure the highlighted fields are updated accordingly:

Monitoring Details

Outbreak: EBOLA-2022-UGANDA

Collection Freq: Once Frequency Unit: per Day

Monitoring Period: 21 Period Unit: Days

Start Monitoring Date (mm/dd/yyyy): 10/12/2022

End Monitoring Date (mm/dd/yyyy): 11/03/2022

Highest Monitoring Level: Active Monitoring

Contact Reassessed?: Yes No

Contact Deceased?: Yes No

Highest Risk Level: Low

Was PEP vaccine offered?: Yes No Unknown

Was PEP vaccine administered?: Yes No Unknown

Individual contacted at least once by public health: Yes No Unknown

Monitoring Symptoms

Add a day + View All ☰

Days List									
Day	Date	Investigator	Status	Risk Level	Action	Temp			
3	10/15/2022	NICKERTJ1211	Active Monitoring	Low	Contacted	98.7	View	Edit	🗑️
9	10/21/2022	NICKERTJ1211	Active Monitoring	Low	Contacted	98.7	View	Edit	🗑️
17	10/29/2022	NICKERTJ1211	Active Monitoring	Low	Contacted	98.7	View	Edit	🗑️
18	10/31/2022	NICKERTJ1211	Active Monitoring	Low	Contacted	98.7	View	Edit	🗑️

- Temperature
- Vomiting, bloody
- Vomiting
- Unexplained bruise
- Rash, unspecified
- Rash, purpuric
- Rash, petechial
- Rash, maculopapular
- Headache
- Fever
- Diarrhea, bloody

Additional Assessment

Client indicated that he had been given ebola information/education upon landing in Atlanta. Other than some jet lag client is feeling well with no sign/symptoms of illness.

- **Start Monitoring Date** = last date the traveler was in Marburg-affected country.
 - Note, this is the first day of the monitoring period, **NOT** the date the LHD initiated monitoring the individual.
 - MDHHS will pre-populate this field as the “date of departure” for flight entering the USA, if provided. In absence of “date of departure”, “arrival date” to the USA will be used. Please update according to conversation with the traveler.
- **End Monitoring Date** = 21 days from the last date the traveler was in a Marburg-affected country.
 - If the traveler plans to leave MI prior to end of active monitoring period, AND the LHD plans to end the active monitoring relationship at that time, PLEASE UPDATE the End Monitoring Date accordingly, and provide an explanation in the “Additional Assessment” section of the Data Points tab.

- **Highest Risk Level, Collection Frequency, and Frequency Unit** = decided according to Marburg TEAM Protocol.
- **Days List** = complete after every attempted or successful contact with the traveler, noting the outcome of the call with the “Action” field.
 - The first successful contact with the traveler noted here is used in outcome reporting to the CDC, which is completed by the TH Team.
- **Additional Assessment** = any additional details pertinent to your conversation with traveler may be entered here. If traveler will be leaving LHD jurisdiction prior to 21 days post-exposure, please provide details and explanation here.

□ Update fields on “Overview” tab and ensure they are up-to-date after each call:

Language: English	Risk Assessment: Low	Referral Date: 10/14/2022
Reporting Source: Federal Referral	Source Description: SDX- DGMQ	Health Status: Well
Completion Date: 11/03/2022	LHJ User: NICKERT,JANE L	MDSS Case ID:
Monitoring Status: Complete	Contact ID: 14027026	High Risk Setting: No
Source:	Contact Outbreak ID: 14027029	

- **Risk Assessment** = listed according to the TEAM Protocol
- **Completion Date** = the last day the LHD performed Active Monitoring with the individual.
- **Health Status** = unless the traveler has been diagnosed with Marburg, status should be “Well”. If traveler has symptoms, and testing is pending, update status to “Unknown”.
- **Monitoring Status** = after initial attempt at contact with traveler, update from “New” to the best option in the menu.
 - If active monitoring, select “Active”, and change to “Complete” once monitoring is concluded.
 - If no action or changes have been documented in OMS within 7 days of Referral Date, the record will be considered “Lost to Follow Up” and changed accordingly.
- **Referral Date** = date that MDHHS entered the contact into OMS
 - Please **do not update** or change this date.